Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | MST1R pos PIK3CA E545K |
| Therapy | Buparlisib |
| Indication/Tumor Type | breast cancer |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| MST1R pos PIK3CA E545K | breast cancer | predicted - sensitive | Buparlisib | Preclinical - Cell culture | Actionable | In a preclinical study, BKM120 decreased viability of a breast cancer cell line expressing the constitutively active short isoform of MST1R (RON) and PIK3CA E545K in culture (PMID: 26289070). | 26289070 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (26289070) | Preclinical Efficacy of Ron Kinase Inhibitors Alone and in Combination with PI3K Inhibitors for Treatment of sfRon-Expressing Breast Cancer Patient-Derived Xenografts. | Full reference... |